Sign In
Buy NVO
$47.41
-0.0100 (-0.0211%)
At Close: Jun 24, 2026
Novo Nordisk's once-weekly basal insulin icodec recommended for marketing approval in Europe
12:33pm, Thursday, 21'st Mar 2024
Danish drugmaker Novo Nordisk on Thursday said its once-weekly basal insulin icodec for treatment of diabetes in adults had received a recommendation for marketing authorisation from the European Medi
7 Stocks That Are Creating a Buzz on Wall Street
10:51am, Thursday, 21'st Mar 2024
What a difference a Fed meeting can make. Stocks are again ripping higher after the U.S. Federal Reserve signalled that it still expects to deliver three interest rate cuts this year.
Novo Nordisk's New Weight Loss Drug Could Be Better Than Ozempic and Wegovy
10:15am, Thursday, 21'st Mar 2024
Novo Nordisk recently released trial results for its weight loss pill amycretin. In an early-stage trial, the drug performed better than Wegovy.
German health ministry says Ozempic exports are not a concern
05:25am, Thursday, 21'st Mar 2024
Germany's health ministry said that no large volumes of diabetes drug Ozempic are being exported out of the country, quashing a suggestion by the nation's drugs regulator that outbound trade in the dr
3 Biopharma Stocks Predicted to Soar in Q2 2024
01:49pm, Wednesday, 20'th Mar 2024
Biopharma stocks have been among the most popular and well-performing stocks this year. With recent trends in weight loss drugs and clinical advancements in treating illnesses, this market is set for
Will Novo Nordisk Overtake Eli Lilly as the Most Valuable Healthcare Stock?
08:30am, Wednesday, 20'th Mar 2024
Novo Nordisk's shares have benefited from some recent positive developments. The delay in the approval of donanemab has held back Eli Lilly's valuation.
A new study cites the health risks of intermittent fasting. Could it lift Ozempic sales?
07:01pm, Tuesday, 19'th Mar 2024
A new medical study is raising concerns over whether intermittent fasting, a weight-loss method that's gained attention in recent years, could pose heart-health risks.
Time to be "Overweight" Viking Therapeutics
04:00pm, Tuesday, 19'th Mar 2024
A rising obesity rate and the desire for a quick fix are driving the burgeoning weight loss industry. Stock Strategist Andrew Rocco explains why VKTX stands to benefit the most.
3 Top Stocks to Watch From the Best International Money Managers
11:00am, Tuesday, 19'th Mar 2024
#Morningstar #NovoNordisk #StockInvesting Managers of highly rated funds own these foreign stocks. Should you?
Is Madrigal Pharmaceuticals Stock a Better Buy Than Eli Lilly and Novo Nordisk After Its Huge FDA Win?
05:50am, Tuesday, 19'th Mar 2024
Last week's FDA approval of Rezdiffra in treating NASH is a huge milestone for Madrigal. Lilly and Novo Nordisk look much more impressive than Madrigal in most ways.
Novo Nordisk (NVO) Rises Yet Lags Behind Market: Some Facts Worth Knowing
06:56pm, Monday, 18'th Mar 2024
Novo Nordisk (NVO) concluded the recent trading session at $132.89, signifying a +0.39% move from its prior day's close.
Earnings Growth & Price Strength Make Novo Nordisk (NVO) a Stock to Watch
10:31am, Monday, 18'th Mar 2024
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Focus List.
Weight loss drug Wegovy is now approved for heart health — but that won't mean broad insurance coverage just yet
08:55am, Monday, 18'th Mar 2024
Some health plans and employers are still reluctant to cover Wegovy due to its hefty price tag, which they say could significantly strain their budgets.
Novo Nordisk Isn't in The "Magnificent Seven," but Here's Why I Think It Should Be
02:28pm, Sunday, 17'th Mar 2024
Novo Nordisk is a leader and innovator in the diabetes drug market. The pharmaceutical company is making strides in obesity care, too.
Novo Nordisk Is Already Working on Wegovy's Successor -- Time to Buy?
09:46am, Sunday, 17'th Mar 2024
Novo Nordisk recently presented encouraging phase 1 results for an oral obesity treatment candidate. The company has many more promising programs in its early-stage pipeline.
